NILCO biomarkers in breast cancer from Chinese patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Colbert, Laronna S ^a,b   Wilson, Kaamilah ^a   Kim, Sungjin ^c   Liu, Yuan ^c   Oprea Ilies, Gabriela ^d   Gillespie, Corey ^a   Dickson, Toi ^a   Newman, Gale ^a   Gonzalez Perez, Ruben Rene ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; JAGGED1; KI 67 ANTIGEN; LEPTIN; LEPTIN RECEPTOR; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN DLL4; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL NUCLEUS; CHINESE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; BIOSYNTHESIS; CANCER STAGING; GENETICS; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; ESTROGENS; FEMALE; HUMANS; INTERLEUKIN-1; LEPTIN; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, NOTCH; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899471056     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-249     Document Type: Article

References (45)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
2. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008, 68:5226-5235. 10.1158/0008-5472.CAN-07-5744, 18593923.
3. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010, 66:33-38. 10.1016/j.maturitas.2010.01.019, 20181446.
4. Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol 2013, 382(25):570-582.
5. Mohamed A, Krajewski K, Cakar B, Ma CX. Targeted therapy for breast cancer. Am J Pathol 2013, 183:1096-1112. 10.1016/j.ajpath.2013.07.005, 23988612.
6. Stylianou S, Clarke BR, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006, 66:1517-1525. 10.1158/0008-5472.CAN-05-3054, 16452208.
7. Guo S, Liu M, Gonzalez-Perez RR. Role of notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 1815, 2011:197-213.
8. Shi W, Harris AL. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 2006, 11:41-52. 10.1007/s10911-006-9011-7, 16947085.
9. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005, 65:8530-8537. 10.1158/0008-5472.CAN-05-1069, 16166334.
10. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH. Targeting notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 1806, 2010:258-267.
11. Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene 2010, 29:201-213. 10.1038/onc.2009.323, 19838210.
12. Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, Erşahin T, Rajan P. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol 2012, 20:139-145.
13. Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, Hsieh C-C, Altieri DC. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008, 10:R97. 10.1186/bcr2200, 2656893, 19025652.
14. WHO World Health Organization Fact Sheet for World Wide Prevalence of Obesity. 2006, http://www.who.int/mediacentre/factsheets/fs311/en/index.html, WHO.
15. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ, Holick CN, Hampton JM, Stampfer MJ, Willett WC, Newcomb PA. Body mass index before and after breast cancer diagnosis: associations with All-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 2009, 18:1403-1409. 10.1158/1055-9965.EPI-08-1094, 2715918, 19366908.
16. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011, 11:886-895. 10.1038/nrc3174, 22113164.
17. Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PloS One 2011, 6:e21467. 10.1371/journal.pone.0021467, 3121792, 21731759.
18. Gillespie C, Quarshie A, Penichet M, Gonzalez-Perez RR. Potential role of leptin signaling in DMBA-induced mammary tumors by Non-responsive C57BL/6 J mice Fed a high-Fat diet. J Carcinogene Mutagene 2012, 3:132.
19. Battle M, Gillespie C, Quarshie A, Lanier V, Torroella-Kouri M, Gonzalez-Perez RR. Obesity induced leptin-Notch signaling axis in breast cancer. Int J Cancer 2014, 134:1606-1616.
20. Gonzalez-Perez RR, Lanier V, Newman G. Leptin's proangiogenic signature in breast cancer. Cancers 2013, 5:1140-1162. 10.3390/cancers5031140, 3795383, 24202338.
21. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, Rueda BR. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 2006, 281:26320-26328. 10.1074/jbc.M601991200, 16825198.
22. Saxena NK, Vertino PM, Anania FA, Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 2007, 282:13316-13325. 10.1074/jbc.M609798200, 2923657, 17344214.
23. Ferla R, Bonomi M, Otvos L, Surmacz E. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer 2011, 11:303. 3146945, 21771332.
24. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta 1825, 2012:207-222.
25. Gonzalez RR, Leary K, Petrozza JC, Leavis PC. Leptin regulation of interleukin-1 (IL-1) system in endometrial cells. Mol Hum Reprod 2003, 9:151-158. 10.1093/molehr/gag022, 12606591.
26. Palomino WA, Fuentes A, Gonzalez RR, Gabler F, Boric MA, Vega M, Devoto L. Differential expression of endometrial integrins and progesterone receptor during the window of implantation in normo-ovulatory women treated with clomiphene citrate. Fertil Steril 2005, 83:587-593. 10.1016/j.fertnstert.2004.11.020, 15749485.
27. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther 2013, 139:95-110. 10.1016/j.pharmthera.2013.02.003, 23458608.
28. Chen X, Zha X, Chen W, Zhu T, Qiu J, Røe OD, Li J, Wang Z, Yin Y. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer. Biomed Pharmacother 2013, 67:22-30.
29. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, Ando S. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004, 279:19908-19915. 10.1074/jbc.M313191200, 14985328.
30. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin induced migration of breast carcinoma cells. Endocr Relat Cancer 2011, 18:413-428. 10.1530/ERC-11-0075, 3361735, 21555376.
31. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. Surg Res 2008, 149:9-14.
32. Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, De Amicis F, Fuqua SA, Catalano S, Andò S. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol 2013, 7:379-391. 10.1016/j.molonc.2012.11.002, 23228483.
33. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008, 68:9712-9722. 10.1158/0008-5472.CAN-08-1952, 3180854, 19047149.
34. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009, 11:R36. 10.1186/bcr2321, 2716504, 19531256.
35. Otvos L, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 2011, 10:1578-1584.
36. Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, Erşahin T, Rajan P. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol 2012, 20:139-145.
37. Kim SB, Chae GW, Lee J, Park J, Tak H, Chung JH, Park TG, Ahn JK, Joe CO. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ 2007, 14:982-991.
38. Dong Y, Li A, Wang J, Weber JD, Michel LS. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 2010, 70:5465-5474. 10.1158/0008-5472.CAN-10-0173, 20570903.
39. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, Rich JN, Hjelmeland AB, Vasanji A, Berger NA, Lathia JD, Reizes O. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer 2013, 20:797-808. 10.1530/ERC-13-0329, 24025407.
40. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638. 10.1056/NEJMoa021423, 12711737.
41. Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A 2012, 109:829-834. 10.1073/pnas.1114438109, 3271911, 22207628.
42. Gilbert CA, Slingerland JM. Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression. Ann Rev Med 2013, 64:45-57. 10.1146/annurev-med-121211-091527, 23121183.
43. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 1807, 2011:664-678.
44. Zhang Y, Bellows CF, Kolonin MG. Adipose tissue-derived progenitor cells and cancer. World J Stem Cells 2010, 2:103-113. 10.4252/wjsc.v2.i5.103, 3097931, 21607127.
45. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007, 1:177-188.